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A B S T R A C T
The role of damage-associated molecular patterns in multiple sclerosis (MS) is under investigation. Here, we
studied the contribution of circulating high mobility group box protein 1 (HMGB1) and mitochondrial DNA
(mtDNA) to neuroinflammation in progressive MS. We measured plasmatic mtDNA, HMGB1 and pro-in-
flammatory cytokines in 38 secondary progressive (SP) patients, 35 primary progressive (PP) patients and 42
controls. Free mtDNA was higher in SP than PP. Pro-inflammatory cytokines were increased in progressive
patients. In PP, tumor necrosis factor-α correlated with MS Severity Score. Thus, in progressive patients, plas-
matic mtDNA and pro-inflammatory cytokines likely contribute to the systemic inflammatory status.
1. Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating
disease affecting the central nervous system (CNS), featured by a het-
erogeneous clinical course (Lublin et al., 2014). In MS, inflammation is
an important component of neurodegeneration, and the mechanisms
driving disease development deeply involve both innate and adaptive
immune system (Dendrou et al., 2015; Mayo et al., 2012), as well as
innate-like T lymphocytes (Bianchini et al., 2017; De Biasi et al., 2016).
However, the stimulus (or stimuli) and mechanisms that trigger and
maintain inflammatory processes are still a matter of debate. Increasing
evidence exists for a role of molecules containing the so-called damage-
associated molecular patterns (DAMPs). These molecules are normally
present inside all cells and, when released into the extracellular milieu
by damaged or dead/dying cells, they are able to elicit a sterile pro-
inflammatory response by activating the innate immune system (Krysko
et al., 2013).
Pioneering observations reported that high mobility group box
protein 1 (HMGB1, a non-histone DNA-binding protein acting as tran-
scriptional regulator and as nucleosome stabilizer) plays a role either in
MS or in experimental autoimmune encephalomyelitis (Andersson
et al., 2008). Recent studies have also suggested putative associations
between DAMPs arising from mitochondrial (mt) components, parti-
cularly circulating cell-free mtDNA, and MS progression (Leurs et al.,
2018; Lowes et al., 2019). Such DAMPs could induce the production of
cytokines and other pro-inflammatory mediators that trigger and
maintain the inflammatory environment, leading to a dysregulated and
imbalanced cytokine network, well described in MS patients (Kallaur
et al., 2017; Khaibullin et al., 2017).
In recent years, the identification of molecules and mechanisms
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contributing to the establishment and maintenance of inflammatory
processes in MS has advanced, but studies concerning and correlating
DAMPs like HMGB1 or free mtDNA and cytokine levels (as a marker of
pro-inflammatory status) in MS patients are limited, and have often
yielded discrepant results. Thus, we investigated the contribution of
circulating HMGB1 and mtDNA, along with main pro-inflammatory
cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-
6, IL-8 and interferon (IFN)-γ to inflammation and neurodegeneration
in the progressive forms of MS. To address this issue, we evaluated
HMGB1, free mtDNA and pro-inflammatory cytokines in plasma sam-
ples from patients affected by primary or secondary progressive forms
of MS, and assessed their correlation with disease progression.
2. Subjects and methods
2.1. Study subjects
Patients were recruited at the MS Center of the Neurology Clinic of
the University Hospital-NOCSAE in Modena during their planned rou-
tine visits, in the framework of a recently published clinical study (De
Biasi et al., 2016; De Biasi et al., 2019). All subjects gave written in-
formed consent in agreement with the Declaration of Helsinki. The
protocol of this study was approved by the Ethical Committee of
Modena (Prot. 2483/CE).
We included all patients aged between 18 and 75 years old, and
diagnosed with MS according to the 2010 revised McDonald criteria
(Polman et al., 2011). Patients with concomitant infections (viral or
bacterial) and with non-steroidal anti-inflammatory drug intake within
the preceding 48 h were excluded. Patients treated with pulsed steroids
within the last month, those on chronic corticosteroid or im-
munosuppressant therapy, and patients treated with im-
munomodulatory or immunosuppressant therapy in the previous
6months were excluded as well.
We enrolled a total of 73 untreated, progressive MS patients: 38
with secondary progressive (SP) form and 35 with primary progressive
(PP) form, all without clinical activity/superimposed relapses in the
preceding 2 years. For each patient, the following parameters were re-
corded: demographic (sex, age) and clinical [disease duration, MS
Severity Score (MSSS) and Kurztke's Expanded Disability Status Scale
(EDSS)]. Forty-two healthy subjects, without a history of autoimmune
diseases and immunosuppressant or corticosteroid therapy, were
chosen as controls (CTR).
Table 1 summarizes the characteristics of MS patients and CTR
enrolled in the study. SP patients had higher EDSS (p= .016; Mann-
Whitney test) and disease duration (p= .003; Mann-Whitney test).
Venous blood was collected from each subject into EDTA tubes.
Then, plasma was separated from blood cells according to standard
procedures and stored at −80 °C until use.
2.2. Quantification of circulating mtDNA
Plasma content of cell-free mtDNA was measured by quantitative
real-time PCR as previously described (Nasi et al., 2016; Pinti et al.,
2014). PCR was performed using CFX96 Touch (BioRad, Hercules, CA,
USA); all analyses were performed in triplicate.
2.3. Analysis of HMGB1 and cytokine plasma levels
We quantified plasma levels of TNF-α, IL-1β, IL-6, IL-8 and IFN-γ by
Human HS Cytokine A Custom Premix 5 Plex Magnetic Luminex
Performance Assay (R&D, Minneapolis, MN, CAN); HMGB1 was mea-
sured by Human HMGB1 ELISA Kit (Fine Test, Zone, Wuhan, China).
2.4. Statistical analysis
Quantitative variables between groups were compared by Mann-
Whitney test. An explorative Spearman correlation test and a sub-
sequent linear regression analysis were performed to investigate pos-
sible correlations between demographic/clinical parameters and ex-
perimental data. A p value< .05 was considered statistically
significant. Data shown in graphs are represented as the mean ± SEM.
Statistical analyses were performed using Prism 6.0 (GraphPad
Software Inc., San Diego, CA, USA).
2.5. Protein interaction network analysis
Interactions between cytokines selected among those differently
expressed between MS patients and CTR were analyzed by the bioin-
formatics tool Search Tool for the Retrieval of Interacting Genes/
Proteins (STRING, version 11.0), using high confidence (score 0.7)
(Franceschini et al., 2013).
3. Results
3.1. Plasmatic mtDNA is higher in SP patients compared to PP patients
We could measure circulating mtDNA in plasma samples from 26 PP
patients, 34 SP patients and 30 CTR, comparable for age (p > .05). As
shown in Fig. 1A, free mtDNA was significantly higher in SP patients
than PP patients (p= .0040), and also higher than CTR.
3.2. Pro-inflammatory cytokine levels are increased in plasma from
progressive MS patients
The quantification of HMGB1 and pro-inflammatory cytokines was
performed on 25 PP patients, 25 SP patients and 30 CTR. No significant
differences were found in plasmatic HMGB1 between CTR and MS pa-
tients or between SP and PP patients, which displayed similar levels
(CTR=1175.45 ± 84.55 pg/mL, SP= 1177.78 ± 108.54 pg/mL,
PP=1077.06 ± 81.34 pg/mL; data not shown). In PP, plasma con-
centrations of TNF-α and IL-8 were higher compared to CTR or com-
pared to SP and CTR, respectively (p= .0229, p= .0073 and
p= .0195; Fig. 1B and F), while all progressive MS patients had higher
levels of IL-6 and IL-1β than CTR (SP: p= .0038 and p= .0002, PP:
p= .0471 and p= .0240; Fig. 1C and D). Despite not reaching statis-
tically significant differences, IFN-γ levels showed trends towards in-
creased expression in PP patients than in SP patients and CTR, as well as
in SP patients than CTR (Fig. 1E).
STRING analysis revealed that the cytokines up-regulated in MS
plasma samples were strongly connected, and highlighted the relevance
of TNF-α, positioned in the center of the cluster (Fig. 2A).
3.3. Correlations among plasma and clinical parameters
When correlating experimental data with demographic/clinical
Table 1
Demographical and clinical characteristics of progressive MS patients and CTR.
CTR SP PP
Number 42 38 35
Age (years)* 53.00 ± 1.56 58.55 ± 1.11 58.70 ± 1.10
Gender (M/F) 18/24 13/25 12/23
Disease duration (months)* 291.30 ± 17.81 205.20 ± 19.10
MSSS* 6.33 ± 0.33 6.00 ± 0.39
EDSS* 6.47 ± 0.17 5.43 ± 0.31
Data are given as absolute numbers or as mean ± standard error of the mean
(*).
CTR: healthy controls; SP: secondary progressive patients; PP: primary pro-
gressive patients; M/F: Male/Female; MSSS: Multiple Sclerosis Severity Score;
EDSS: Expanded Disability Status Scale.
M. Nasi, et al. Journal of Neuroimmunology 338 (2020) 577107
2
Fig. 1. Plasma levels of free mtDNA and pro-inflammatory cytokines in progressive MS patients and CTR.
(A) Quantification of cell-free mtDNA in plasma from SP MS (N=34), PP MS (N=26) and CTR (N=30). (B) TNF-α, (C) IL-6, (D) IL-1β, (E) IFN-γ and (F) IL-8
concentrations in plasma from SP MS (N=25), PP MS (N=25) and CTR (N=30).
CTR: healthy controls; SP: secondary progressive patients; PP: primary progressive patients. *p < .05; **p < .01; ***p < .001.
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parameters, we observed that in PP plasma levels of TNF-α directly
correlated with MSSS (p= .0298, R2= 0.1971; Fig. 2B).
4. Discussion
Understanding the molecules and mechanisms triggering and
maintaining inflammatory processes in MS is crucial for the identifi-
cation of new, suitable therapeutic targets. DAMPs such as circulating
HMGB1 and mtDNA are receiving increasing attention as molecules
able to elicit sterile inflammation in several conditions characterized by
a chronic inflammatory status (Cossarizza et al., 2011; Pinti et al., 2014;
Pinti et al., 2012). Here, we observed that plasmatic mtDNA was higher
in SP than PP, while HMGB1 levels did not vary between progressive
MS patients and CTR or between SP and PP patients.
Recent studies have associated decreased levels of circulating cell-
free mtDNA in the cerebrospinal fluid (CSF) from patients afflicted by
Alzheimer's and Parkinson's disease with neurodegeneration (Podlesniy
et al., 2013; Pyle et al., 2015). Similarly, reduced concentrations of
circulating mtDNA were detected in the CSF of end-stage progressive
MS with evidence of neurodegeneration (Lowes et al., 2019). Con-
versely, a significantly higher level of CSF cell-free mtDNA was found in
relapsing-remitting (RR) MS patients, as well as an inverse correlation
between circulating mtDNA concentration and time since disease onset,
suggesting that free mtDNA level may reflect early, active inflammatory
activity (Varhaug et al., 2017).
We are well aware that variations in plasmatic mtDNA can be due to
the release of DAMPs from different organs and cell types. However,
although CSF better mirrors the inflammatory processes occurring in-
side the CNS, plasma concentrations of cell-free mtDNA likely indicate
the general degree of inflammatory status. Thus, our findings suggest
that free mtDNA released in plasma could contribute to the systemic
inflammatory status of patients, and that SP form is characterized by a
higher inflammatory milieu. In particular, the observation that circu-
lating mtDNA levels did not show statistically significant differences
between PP patients and CTR, but were increased in SP patients com-
pared to PP patients could indicate that the implication of free mtDNA
in inflammation is secondary and associated to a chronic stage of the
disease where cell shrinkage may play a role, possibly peculiar of SP
form. In any case, this finding could suggest that a difference exists
between the two progressive forms of MS, even though these two
phenotypes encompass the same disease spectrum and are considered
clinically overlapping (Ontaneda et al., 2017).
Hence, plasmatic mtDNA could be the secondary and unspecific
result of cell shrinkage associated to disease. Another possibility is that
free mtDNA could come from nervous tissue mt damage. Alternatively,
taking into account the previously unrecognized observation that per-
ipheral blood leukocytes are able to rapidly eject interferogenic mtDNA
as web filament structures upon appropriate stimulation (Ingelsson
et al., 2018), we hypothesize that mtDNA webs could be the source of
the increased circulating mtDNA, but this speculation needs further
deepening.
As for HMGB1, other investigators variably reported increased
(Malhotra et al., 2015) or unchanged (Sternberg et al., 2016) serum
levels in MS patients compared to healthy subjects. In particular, Mal-
hotra et al. observed the highest HMGB1 serum levels in RR MS when
stratifying patients for clinical forms, and reported an increased
HMGB1 serum concentration in SP than CTR, with a similar trend in PP
(Malhotra et al., 2015). However, the discrepancies with our findings
could be attributed to the different and smaller cohort of patients en-
rolled in that study.
We also found that in PP plasma levels of TNF-α and IL-8 were
higher compared to CTR or compared to both SP and CTR, respectively,
while all progressive MS patients had increased concentrations of IL-6
and IL-1β. In addition, similarly to TNF-α and IL-8 patterns, IFN-γ levels
showed trends towards increased expression in PP patients than in SP
patients and CTR, as well as in SP patients than CTR, even if not
reaching statistically significant differences. Several studies have in-
vestigated the levels of many cytokines in CSF, serum and plasma
samples from MS patients with different forms and treatments of the
disease (Kallaur et al., 2017; Khaibullin et al., 2017; Martins et al.,
2011), often yielding conflicting results, but overall demonstrating a
marked increase of pro-inflammatory molecules in MS patients. Of note,
most of the previous reports investigated the RR form of MS or com-
prised in the progressive group both SP and PP patients. Our results
further highlight the imbalanced cytokine network that exists in pro-
gressive MS patients and that likely modulates disease activity and
progression, and suggest the possibility to develop agents targeting
cytokines or their receptors as novel therapies for MS. As expected
because of the common inflammatory nature shared by the mediators
investigated and their well-known relationships, STRING analysis con-
firmed the existence of strong interactions among the cytokines dif-
ferently expressed by SP and PP, accounting, at least in part, for the
alterations we observed in their cytokine profile.
Statistically significant correlations between cytokine levels and
Fig. 2. STRING analysis and correlations between experimental and clinical parameters.
(A) Plasma STRING analysis for the interactions between TNF-α, IL-6, IL-1β, IFN-γ and IL-8: green= activation; red= inhibition; yellow= transcriptional reg-
ulation.
(B) Scatterplot and linear regression analysis between plasma levels of TNF-α and MSSS in PP MS (N=25).
MSSS: Multiple Sclerosis Severity Score. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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demographic/clinical parameters were found between plasma levels of
TNF-α and MSSS in PP. An association between the CSF level of TNF-α
and disease severity and progression in chronic progressive MS patients
has been known since 1991, supporting the role for this cytokine in the
progression of MS (Sharief and Hentges, 1991). Interestingly, the
STRING analysis highlights the relevance of TNF-α, positioned in the
center of the connections with the up-regulated cytokines, even if this
analysis took into account a low number of molecules. This correlation
was present only in PP patients, shedding light again on the differences
concerning some inflammatory components in the SP and PP forms,
probably due to the different disease course that leads to that endpoint.
Overall, our study has some limitations, including limited DAMP
testing, poor cytokine profiling, scarce correlation with in vivo cell or
humoral immunological response of patients, and poor testing of Toll-
like receptor 9 activation. However, our data indicate that in pro-
gressive MS increased plasma levels of free mtDNA, in synergy with
pro-inflammatory cytokines, likely contribute to the systemic in-
flammatory status of these patients, though the inflammatory compo-
nent could be differently activated in the two progressive forms of the
disease.
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